Newsletter

View this email in your browser

Good morning traders,

 Let's get right to it. The timing looks perfect here. The chart is sitting just over the 50 day with an RSI of 44. http://stockcharts.com/h-sc/ui?s=xxii

 22nd Century Group, Inc. (NYSE-MKT: XXII) is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking.

 XXII owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world.

 In late December 2015 (NYSE: XXII) submitted an application for a Modified Risk Tobacco Product (MRTP) - more notably their proprietary Very Low Nicotine (VLN) products. In early January 2016, (NYSE: XXII) was contacted by the FDA requesting a meeting. In Mid January (NYSE: XXII) met with the FDA - 42 people attended on behalf of the FDA. Such a quick response shows how serious the FDA is about this issue.

 There is considerable third party published data on the benefits of reducing the exposure to nicotine and it is in the interest of the general health of the nation!

 In late April, Health Canada made a statement that they are looking into forcing tobacco companies into making smoking less addictive. See the two articles below.

 Quote from health Canada:

 ".....reducing the nicotine level of cigarettes is the most-discussed means of lessening their addictiveness...."

 Health Canada articles:
 http://www.techtimes.com/articles/152264/20160421/health-canada-mulls-forcing-tobacco-companies-to-make-cigarettes-less-addictive.htm

 http://news.nationalpost.com/news/canada/health-canada-looks-at-forcing-tobacco-companies-to-make-cigarettes-less-addictive

 The CEO of $152B market Cap, Philip Morris CEO is now talking about "reduced risk" ....(NYSE: XXII) holds the patents to help them get there!
 http://www.reuters.com/article/britain-tobacco-idUSL5N18G3CB

 Philip Morris said it would keep trying to "focus on efforts to develop and commercialize scientifically substantiated reduced-risk products".

 CNBC recent Interview
 http://www.cnbc.com/2015/05/07/philip-morris-aims-for-reduced-risk-products.html

 Recent price target of $4.50 issued by Chardan- Talks about substantial value in Cannabinoid research as well. - http://broadstreetalerts.com/wp-content/uploads/2016/05/XXII_2016-05-16-Chardan-1.pdf

 This should get everyone started, we will be back with an updated report.

 The Team

 DISCLAIMER

 Small Cap Traders is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

 Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

 PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

 Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC has been compensated twenty five thousand dollars cash via bankwire by star media for a two to three day investor relations campaign of XXII. SCS LLC owners and operators do not hold any positions in XXII. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

 The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

 In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.

 SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 Our mailing address is:

Small-Cap Street LLC

10005 Wall Street, New York, NY
New York, NY 10005

Add us to your address book

 Want to change how you receive these emails?
 You can update your preferences or unsubscribe from this list

Stocks covered:	Compensation:	Avg $ Volume for Period:
XXII	$25000	441329
Max Profit: 13.46 %	Gain at close: 8.85 %
*We think that this promoter is a part of a group of promoters.

Newsletter

New_NYSE_profile May 23, 2016 09:30